Skip to main content
Erschienen in: Annals of Hematology 11/2012

01.11.2012 | Original Article

The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation

verfasst von: C. Hicks, A. Trickett, Y. L. Kwan, S. Ramanathan

Erschienen in: Annals of Hematology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Generally, patients’ actual body weight (ABW) is used to calculate the number of CD34+ cells to be harvested for autologous haematopoietic progenitor cell (HPC) transplantation. In our institution, ‘overweight’ patients weighing at least 25 % more than their ideal body weight (IBW) have their adjusted ideal body weight (AdjIBW) used for determination of blood volume to be processed to achieve a minimum target of CD34+ cells per kilogram, as well as CD34+ cell dosage calculation at transplant. AdjIBW is calculated as follows: AdjIBW = IBW + 0.25 × (actual weight − IBW). We have used AdjIBW for 65/153 patients who have had autologous HPC harvests, with a median AdjIBW of 69 kg (range, 50–110 kg). Median actual weight was 90 kg (range, 62–175 kg). Median volume of peripheral blood processed to achieve a minimum 2 × 106 CD34+ cells/kg for these patients was 13.2 L (range, 5–35 L), and the median CD34+ cells × 106/kg collected for AdjIBW was 6.3 (range, 1.7–33). For normal-weight patients (n = 88; median ABW, 75 kg; range, 49–98 kg), the corresponding median apheresis volume was 16 L (range, 7–24 L), and median CD34+ cells × 106/kg harvested was 4.5 (range, 1.4–15.9). In total, 35 in a total transplant cohort of 82 patients had AdjIBW used to determine CD34+ cell dose at time of transplant, with a median of 4.5 × 106/kg, (if their ABW was used in the calculation; 3.1 × 106/kg), compared to median dose of 3.2 × 106/kg ABW for the normal-weight patient cohort. All patients engrafted with no significant difference between median times to neutrophil and platelet engraftment for the overweight (13 and 15 days, respectively) compared with normal-weight (12 and 14 days, respectively) patient cohorts. We conclude that the use of AdjIBW is a useful tool for successful harvest and subsequent transplant for overweight patients, with no adverse effect on engraftment times.
Literatur
1.
Zurück zum Zitat Desikan KR, Tricot G, Munshi NC, Annaissie E, Spoon D, Fassas A et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocycte colony-stimulating factor alone. Br J Haematol 112:242–247PubMedCrossRef Desikan KR, Tricot G, Munshi NC, Annaissie E, Spoon D, Fassas A et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocycte colony-stimulating factor alone. Br J Haematol 112:242–247PubMedCrossRef
2.
Zurück zum Zitat The ABMTRR Steering Committee of the BMTSANZ Australian Bone Marrow Transplant Recipient Registry (ABMTRR) Annual Data Summary 2008 The ABMTRR Steering Committee of the BMTSANZ Australian Bone Marrow Transplant Recipient Registry (ABMTRR) Annual Data Summary 2008
3.
Zurück zum Zitat Pasquini MC, He V, Perez WS (2006) CIBMTR summary slides part 1. CIBMTR Newsletter 12:5–7 Pasquini MC, He V, Perez WS (2006) CIBMTR summary slides part 1. CIBMTR Newsletter 12:5–7
4.
Zurück zum Zitat Bessinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood-stem cells. J Clin Oncol 13:2547–2555 Bessinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood-stem cells. J Clin Oncol 13:2547–2555
5.
Zurück zum Zitat Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt SF et al (2006) Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:553–557PubMedCrossRef Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt SF et al (2006) Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:553–557PubMedCrossRef
6.
Zurück zum Zitat Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al (1999) Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 23:867–873PubMedCrossRef Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al (1999) Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 23:867–873PubMedCrossRef
7.
Zurück zum Zitat Ali MY, Oyama Y, Monreal JN, Winter JN, Tallman MS, Williams SF et al (2003) Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31:861–864PubMedCrossRef Ali MY, Oyama Y, Monreal JN, Winter JN, Tallman MS, Williams SF et al (2003) Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31:861–864PubMedCrossRef
8.
Zurück zum Zitat Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al (2004) Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33:161–164PubMedCrossRef Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M et al (2004) Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 33:161–164PubMedCrossRef
9.
Zurück zum Zitat Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef
10.
Zurück zum Zitat Australian Bureau of Statistics 4364.0 National Health Survey: Summary of Results, 2007–08. Reissued 2009 Australian Bureau of Statistics 4364.0 National Health Survey: Summary of Results, 2007–08. Reissued 2009
11.
Zurück zum Zitat Harousseau J-L, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654PubMedCrossRef Harousseau J-L, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645–2654PubMedCrossRef
12.
Zurück zum Zitat Gren B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133CrossRef Gren B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–133CrossRef
13.
Zurück zum Zitat Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum F et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436–4440PubMed Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum F et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436–4440PubMed
14.
Zurück zum Zitat Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al (2007) How to calculate the quantity of CD34+ cells infused? A single centre cohort study based on actual, ideal or adjusted ideal body weight. Transf Apher Sci 36:275–280CrossRef Topcuoglu P, Soydan EA, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al (2007) How to calculate the quantity of CD34+ cells infused? A single centre cohort study based on actual, ideal or adjusted ideal body weight. Transf Apher Sci 36:275–280CrossRef
15.
Zurück zum Zitat Devine BJ (1974) Gentamicin therapy. Drug Intel Clin Phar 8:650–655 Devine BJ (1974) Gentamicin therapy. Drug Intel Clin Phar 8:650–655
16.
Zurück zum Zitat Trickett AE, Smith S, Kwan YL (2001) Accurate calculation of blood volume to be processed by aphaeresis to achieve target CD34+ cell numbers of PBPC transplantation. Cytotherapy 3:5–10PubMedCrossRef Trickett AE, Smith S, Kwan YL (2001) Accurate calculation of blood volume to be processed by aphaeresis to achieve target CD34+ cell numbers of PBPC transplantation. Cytotherapy 3:5–10PubMedCrossRef
17.
Zurück zum Zitat Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213–226PubMedCrossRef Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213–226PubMedCrossRef
18.
Zurück zum Zitat Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J et al (2009) Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant 43:301–305PubMedCrossRef Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J et al (2009) Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma? Bone Marrow Transplant 43:301–305PubMedCrossRef
19.
Zurück zum Zitat Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW (2007) Ideal body weight correlates better with engraftment after PBSC autograft then actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40:665–669PubMedCrossRef Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW (2007) Ideal body weight correlates better with engraftment after PBSC autograft then actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40:665–669PubMedCrossRef
20.
Zurück zum Zitat Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay MK, McCullough J (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31:521–526PubMedCrossRef Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay MK, McCullough J (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31:521–526PubMedCrossRef
21.
Zurück zum Zitat Zambelli A, Poggi G, Da Prada G, Pedrazzoli P, Cuomo A, Miotti D (1998) Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 18(6B):4705–4708PubMed Zambelli A, Poggi G, Da Prada G, Pedrazzoli P, Cuomo A, Miotti D (1998) Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 18(6B):4705–4708PubMed
22.
Zurück zum Zitat Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan S (2007) Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 36:95–101PubMedCrossRef Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G, Cagirgan S (2007) Clinical side effects during peripheral blood progenitor cell infusion. Transfus Apher Sci 36:95–101PubMedCrossRef
23.
Zurück zum Zitat Ungerstedt JS, Waltz E, Uttervall K, Johansson B-M, Wahlin BE, Nassman P et al (2011) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and haematological recovery. Med Oncol. doi:10.1007/s12032-011-0029-3 Ungerstedt JS, Waltz E, Uttervall K, Johansson B-M, Wahlin BE, Nassman P et al (2011) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and haematological recovery. Med Oncol. doi:10.​1007/​s12032-011-0029-3
Metadaten
Titel
The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation
verfasst von
C. Hicks
A. Trickett
Y. L. Kwan
S. Ramanathan
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 11/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1523-1

Weitere Artikel der Ausgabe 11/2012

Annals of Hematology 11/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.